Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer

By sjmartinez • November 20, 2024

Oh MS, Dumitras C, Salehi-Rad R, Tran LM, Krysan K, Lim RJ, Jing Z, Tappuni S, Lisberg A, Garon EB, Dubinett SM, Liu B. Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer. Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0435. Epub ahead of print. PMID: 39559833.

Tags: Fellow, Hematology/Oncology, Post Doc, Publications, Pulmonary, Critical Care & Sleep Medicine, Veterans Administration

Related Posts

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

Hu X, Curigliano G, Yonemori K, Bardia A, Barrios CH, Sohn J, Lévy C, Jacot W, Tsurutani J, Roborel de Climens A, Wu X, Andrzejuk-Ćwik[...]

Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski[...]

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko[...]